Skip to content
Home
  • Our science
    • What is Mass Transfer drying?
    • History
    • 5 benefits for biologics
    • Targeting high-value vaccines
    • Novel administration routes
  • LaminarPace
    • What is LaminarPace?
    • Mass Transfer drying – a new unit of production
    • Quality by Design and continuous development
    • 3D modelling and Tech Transfer
  • Projects
    • Ziccum’s project portfolio
    • 3-step process
    • Meet the project team
  • News
    • Press Releases
    • Ziccum Updates
  • Investors
    • Business model
    • Portfolio overview
    • Financial reports
    • IR portal
    • Calendar
    • Annual general meetings
    • Rights Issue Q1 2024
    • Rights Issue Q4 2024
    • Corporate governance
    • Owners
    • IR contact
    • Certified advisor
    • Presentations
    • Sustainability
    • Subscribe
  • About us
    • Bankruptcy administrator
    • Management team
    • Contact us

IR portal

Home » Investors » IR portal

Contact

e-mail: info@ziccum.com

ZICCUM AB
Scheelevägen 22
223 63 LUND
Sweden

About us

Ziccum is developing LaminarPace®, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. By reducing drying stress to the active ingredient, LaminarPace® uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and also are highly suitable for novel administration routes.

Subscribe

Receive company data continuously to your inbox

Copyright © 2025 ZiccumTheme by SiteOrigin
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok